Cost-effectiveness analysis of interferon beta in multiple sclerosis: A markov process analysis

Value in Health

Volumn 5, Issue 1, 2002, Pages 44-54

  Nuijten, M J C ^a   Hutton, J ^b  

^a MEDTAP International   (Netherlands)

^b MEDTAP International   (United Kingdom)

Author keywords

Cost utility; Interferon; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG SENSITIVITY; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; UNITED KINGDOM;

EID: 0036172372     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.51052.x     Document Type: Article

References (42)

1. Multiple sclerosis and other demyelinating diseases
2. Medical progress: Multiple sclerosis
3. The natural history of multiple sclerosis: A geographically-based study. I. Clinical course and disability; and II. The predictive value of the early clinical course
4. The natural history of multiple sclerosis: A geographically-based study. II. The predictive value of the early clinical course
5. Neuroimaging evaluation in multiple sclerosis
6. The use and misuse of statistics for epidemiological studies of multiple sclerosis
7. Therapeutic advances: Beta-interferon for multiple sclerosis
8. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis
9. The natural history of multiple sclerosis
10. Quality of life in multiple sclerosis
11. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning
12. Economic status of families living with multiple sclerosis
13. The cost of multiple sclerosis
14. Economic evaluation of multiple sclerosis in the UK, Germany and France
15. The national multiple sclerosis survey: Background and economic impact
16. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS
17. The role of disease and demographic factors in the employment of patients with multiple sclerosis
18. Randomised double-blind placebo-controlled study of interferon beta-12a in relapsing/remitting multiple sclerosis
19. Data management in modelling studies: The selection of data sources
20. Prognostic criteria in multiple sclerosis
21. Multivariate analyses of factors associated with unemployment in people with multiple sclerosis
22. A cost-utility analysis of interferon beta for multiple sclerosis
23. Interferons. An overview of their pharmacology
24. Clinical pharmacology of interferon beta-1b and its potential role in multiple sclerosis
25. Mechanisms of action of interferon beta in multiple sclerosis
26. The historical development of interferons as multiple sclerosis therapies
27. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis
28. Placebo-controlled multicenter randomised trial of interferon beta in treatment of secondary progressive multiple sclerosis
29. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
30. Clinical definition for multiple sclerosis treatment trials
31. NICE guidelines
32. Prediction of outcome in multiple sclerosis based on multivariate models
33. Utility. Decision and quality of life
34. Utilities and quality adjusted life years
35. A cost utility analysis of treatment options for gallstone disease: Methodological issues and results